Basic Information
| LncRNA/CircRNA Name | NRAL |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Western blot, Dual luciferase reporter assay, RIP |
| Sample | hepatocellular carcinoma tissue, cell lines (SMMC-7721, HepG2) |
| Expression Pattern | up-regulated |
| Function Description | it was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts. NRAL depletion significantly enhanced CDDP-mediated cytotoxicity and apoptosis in two cisplatin-resistant HCC cell lines. Mechanistically, the results indicated that NRAL regulates Nrf2 expression through miR-340-5p serving as a competing endogenous RNA (ceRNA). |
| Pubmed ID | 30030687 |
| Year | 2018 |
| Title | NRAL Mediates Cisplatin Resistance in Hepatocellular Carcinoma via miR-340-5p/Nrf2 Axis. |
External Links
| Links for NRAL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |